Developing a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication

REFERENCES

• CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998; 47(RR-19):1–39.
   PubMedGoogle Scholar
• CDC. Hepatitis C. MMWR Morb Mortal Wkly Rep 2002; 51(RR-7):64–66.
   Google Scholar
• Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341(8):556–562.
   Google Scholar
• Altice F, Bruce RD. Hepatitis C virus infection in United States correctional institutions. Curr Hepat Rep 2004; 3:112–118.
   Google Scholar
• Sylvestre DL. Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug Alcohol Depend 2002; 67(2):117–123.
   PubMed Web of Science ®Google Scholar
• Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29(3):159–165.
   PubMed Web of Science ®Google Scholar
• McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: Prevalence and public policy implications. J Addict Dis 2001; 20(1):19–31.
   PubMed Web of Science ®Google Scholar
• Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: Knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001; 61(3):211–215.
   PubMed Web of Science ®Google Scholar
• Huber M, Weber R, Oppliger R, Vernazza P, Schmid P, Schonbucher P, Bertisch B, Meili D, Renner EL. Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: An open-label randomized multicenter trial. Infection 2005; 33(1):25–29.
   PubMed Web of Science ®Google Scholar
• Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D, Strathdee SA, Thomas DL. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33(3):126–133.
   PubMed Web of Science ®Google Scholar
• Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005; 12(1):81–85.
   PubMed Web of Science ®Google Scholar
• Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345(3):215–217.
   PubMed Web of Science ®Google Scholar
• Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40(1):120–124.
   PubMed Web of Science ®Google Scholar
• Harris KA, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010; 4(1):20–26.
   PubMed Web of Science ®Google Scholar
• Litwin AH, Harris KA, Jr, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, Kaswan D, Gourevitch MN, Arnsten JH. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat 2008; 37(1):32–40.
   PubMed Web of Science ®Google Scholar
• Martinez AD, Dimova R, Marks KM, Beeder AB, Zeremski M, Kreek MJ, Talal AH. Integrated internist–addiction medicine–hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat 2012; 19, 47–54.
   PubMed Web of Science ®Google Scholar
• Altice FL, Mezger JA, Hodges J, Bruce RD, Marinovich A, Walton M, Springer SA, Friedland GH. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication. Clin Infect Dis 2004; 38(Suppl. 5):S376–S387.
   PubMed Web of Science ®Google Scholar
• Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: A prospective, randomized, controlled trial. Clin Infect Dis 2007; 45(6):770–778.
   PubMed Web of Science ®Google Scholar
• Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: A double-blind, placebo-controlled trial. Psychosomatics 2010; 51(5):401–408.
   Web of Science ®Google Scholar
• McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 1980; 168(1):26–33.
   PubMed Web of Science ®Google Scholar
• Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: New outcome measure for primary care. BMJ 1992; 305(6846):160–164.
   PubMed Web of Science ®Google Scholar
• Sylvestre DL, Zweben JE. Integrating HCV services for drug users: A model to improve engagement and outcomes. Int J Drug Policy 2007; 18(5):406–410.
   PubMed Web of Science ®Google Scholar
• Lertora JJ, Rege AB, Lacour JT, Ferencz N, George WJ, VanDyke RB, Agrawal KC, Hyslop Jr. NE. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1991; 50(4):442–449.
   PubMed Web of Science ®Google Scholar
• Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat 2010; 38(4):338–345.
   PubMed Web of Science ®Google Scholar
• Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Pharmacol Ther, 2010; 32(1):14–28.
   Google Scholar
• Castera L, Zigante F, Bastie A, Buffet C, Dhumeaux D, Hardy P. Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology 2002; 35(4): 978–979.
   PubMed Web of Science ®Google Scholar
• Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36(5 Suppl. 1): S237–S244.
   PubMed Web of Science ®Google Scholar